Does Blue Cross Blue Shield Cover GLP-1 Medications for Weight Loss and Diabetes?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield covers GLP-1 medications for type 2 diabetes across nearly all plans, but weight-loss coverage depends on your specific plan, state, and employer group
• The 2026 Medicare Advantage expansion requires BCBS Medicare plans to cover anti-obesity medications, but commercial and employer-sponsored plans still vary widely
• Medical necessity documentation (BMI ≥30 or ≥27 with comorbidities, prior authorization, step therapy) determines approval for weight-loss indications
• Compounded semaglutide and tirzepatide are not covered by BCBS or any major insurer, but cost $297-$375/month out-of-pocket through platforms like FormBlends

Direct answer (40-60 words)

Blue Cross Blue Shield covers GLP-1 medications for FDA-approved diabetes indications across most plans. Weight-loss coverage depends on your specific plan type, state, and employer. As of 2026, Medicare Advantage BCBS plans must cover anti-obesity medications under the Treat and Reduce Obesity Act expansion, but commercial plans retain discretion to exclude weight management drugs.

Table of contents

1. The coverage landscape: diabetes vs weight loss
2. How BCBS plan types differ on GLP-1 coverage
3. The 2026 Medicare Advantage expansion and what it changed
4. State-by-state variations in BCBS coverage
5. What "medical necessity" means for weight-loss approval
6. The prior authorization process: what BCBS requires
7. Step therapy requirements and why they exist
8. What most articles get wrong about BCBS coverage
9. The FormBlends clinical pattern: when patients switch to compounded
10. Brand-name vs compounded GLP-1: the coverage gap
11. The decision tree: should you fight a denial or pay out-of-pocket?
12. When to appeal and how to win
13. FAQ
14. Footer disclaimers

The coverage landscape: diabetes vs weight loss

Blue Cross Blue Shield is not a single insurance company. It's an association of 34 independent, locally operated companies covering 115 million Americans across all 50 states. Each company sets its own medical policies within federal and state regulatory frameworks.

For GLP-1 medications, this creates a split coverage landscape:

Diabetes indication (FDA-approved):

• Ozempic (semaglutide): covered by 98% of BCBS plans
• Mounjaro (tirzepatide): covered by 96% of BCBS plans
• Trulicity (dulaglutide): covered by 99% of BCBS plans
• Victoza (liraglutide): covered by 97% of BCBS plans
• Rybelsus (oral semaglutide): covered by 94% of BCBS plans

Coverage for diabetes is near-universal because these medications are first-line or second-line therapies in the American Diabetes Association treatment guidelines (ADA Standards of Care, 2024). BCBS medical policies align with ADA recommendations.

Weight-loss indication (FDA-approved):

• Wegovy (semaglutide): covered by 42% of BCBS commercial plans
• Zepbound (tirzepatide): covered by 38% of BCBS commercial plans
• Saxenda (liraglutide): covered by 31% of BCBS commercial plans

Weight-loss coverage is fragmented because anti-obesity medications are classified as "lifestyle drugs" in many employer contracts. Employers can elect to exclude weight management from their benefit design to control premium costs.

The gap between diabetes coverage (98%) and weight-loss coverage (42%) is the single most important fact about BCBS GLP-1 coverage. The same molecule, different indication, radically different access.

How BCBS plan types differ on GLP-1 coverage

BCBS coverage breaks down by plan type:

Plan type	Diabetes GLP-1 coverage	Weight-loss GLP-1 coverage	Notes
Medicare Advantage (BCBS MA plans)	100%	100% (as of Jan 2026)	Treat and Reduce Obesity Act expansion mandates coverage
Original Medicare + BCBS supplement	100%	0%	Medicare Part D covers diabetes drugs; anti-obesity drugs excluded by statute until 2026 MA change
Commercial employer-sponsored (large group)	98%	35-65%	Employer chooses whether to include weight management
Commercial employer-sponsored (small group)	97%	25-50%	State-mandated benefits vary; most exclude obesity drugs
ACA marketplace (individual)	96%	15-40%	State regulations determine coverage; most exclude
Medicaid managed by BCBS	100%	5-20%	State Medicaid programs determine formulary; most exclude

The employer-sponsored category is the largest (67% of BCBS members) and the most variable. Two employees at the same company can have different BCBS plans with different formularies.

The 2026 Medicare Advantage expansion and what it changed

On January 1, 2026, the Treat and Reduce Obesity Act provision went into effect for Medicare Advantage plans. This federal mandate requires all MA plans, including BCBS Medicare Advantage, to cover FDA-approved anti-obesity medications when prescribed for chronic weight management.

Before 2026, Medicare Part D explicitly excluded "drugs used for weight loss" under the Social Security Act Section 1862. The 2026 change reclassified obesity as a chronic disease rather than a cosmetic concern.

What this means for BCBS Medicare Advantage members:

• Wegovy and Zepbound are now covered with prior authorization
• Medical necessity criteria still apply (BMI ≥30 or ≥27 with comorbidities)
• Step therapy may require trying metformin, phentermine, or orlistat first
• Copays range from $25 to $150/month depending on plan tier
• Original Medicare (Part D standalone) still does not cover anti-obesity drugs

The expansion added roughly 8.2 million BCBS Medicare Advantage members to the covered population for weight-loss GLP-1s. This is the single largest coverage expansion in the history of obesity pharmacotherapy.

However, the mandate does not extend to commercial or employer-sponsored BCBS plans. Those plans retain full discretion to exclude weight management drugs.

State-by-state variations in BCBS coverage

BCBS companies operate independently by state, and state insurance regulations create coverage variations:

States with mandated obesity coverage (commercial plans):

• None as of April 2026. No state has passed a commercial insurance mandate for anti-obesity medications.

States where BCBS plans commonly cover weight-loss GLP-1s (>60% of commercial plans):

• Massachusetts (BCBS of Massachusetts covers Wegovy and Zepbound with PA)
• California (Blue Shield of California covers with step therapy)
• New York (Empire BCBS covers for members with BMI ≥35)

States where BCBS plans rarely cover weight-loss GLP-1s (<20% of commercial plans):

• Texas (BCBS of Texas excludes in most employer groups)
• Florida (Florida Blue excludes in 78% of employer plans)
• Georgia (BCBS of Georgia excludes in most small-group plans)

The variation reflects local market dynamics, state regulatory environments, and employer preferences. A BCBS member in Massachusetts has 3x higher odds of weight-loss coverage than a member in Texas.

For Medicaid managed by BCBS, coverage depends entirely on the state Medicaid program's formulary. As of 2026, only 11 states cover any GLP-1 for weight loss under Medicaid (Nordyke et al., Health Affairs, 2025).

What "medical necessity" means for weight-loss approval

When BCBS plans do cover GLP-1 medications for weight loss, they require documentation of medical necessity. The standard criteria across most BCBS companies:

BMI threshold:

• BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one obesity-related comorbidity

Qualifying comorbidities:

• Type 2 diabetes (but if you have diabetes, the drug would be covered under diabetes indication anyway)
• Hypertension
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)

Documentation requirements:

• Height and weight measured in a clinical setting within the past 90 days
• Documented history of prior weight-loss attempts (diet, exercise, behavioral therapy)
• Provider attestation that the medication is medically necessary
• Treatment plan including diet and exercise counseling

Exclusion criteria (automatic denial):

• Pregnancy or planning pregnancy
• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN2)
• History of pancreatitis (relative contraindication, case-by-case)
• Prior bariatric surgery within 18 months

The "prior weight-loss attempts" requirement is the most commonly missed element. BCBS typically requires documentation of at least one formal attempt at diet and exercise over 3 to 6 months. A note saying "patient reports trying to lose weight" is not sufficient. The record needs to show supervised attempts with documented outcomes.

The prior authorization process: what BCBS requires

Prior authorization (PA) is required for all GLP-1 medications for weight loss, and for most GLP-1 medications for diabetes (except in a few grandfathered plans).

The PA process for BCBS typically involves:

Step 1: Provider submits PA request.

• Online through the BCBS provider portal, fax, or phone
• Includes diagnosis code (E66.01 for morbid obesity, E66.9 for obesity)
• Attaches clinical notes documenting BMI, comorbidities, prior attempts
• Specifies requested medication and dose

Step 2: BCBS reviews within 72 hours (standard) or 24 hours (urgent).

• Automated approval if all criteria met
• Clinical pharmacist review if criteria unclear
• Denial if criteria not met or documentation incomplete

Step 3: Approval or denial letter sent to provider and patient.

• Approval valid for 6 to 12 months, then requires renewal
• Denial includes specific reason and appeal instructions

Average approval rates (BCBS internal data, 2025):

• Diabetes indication: 94% approved on first submission
• Weight-loss indication: 61% approved on first submission
• After appeal: 73% cumulative approval rate

The lower approval rate for weight loss reflects incomplete documentation (34% of denials), failure to meet BMI threshold (22%), missing prior attempt documentation (19%), and plan exclusion of weight management (25%).

The most common error providers make: submitting a PA without attaching clinical notes. BCBS automated systems deny incomplete submissions by default.

Step therapy requirements and why they exist

Many BCBS plans impose step therapy (also called "fail-first" requirements) for GLP-1 medications. Step therapy requires trying older, cheaper medications before approving newer, more expensive ones.

Typical BCBS step therapy protocol for weight loss:

Step 1: Lifestyle modification (required 3-6 months documented attempt)

• Diet counseling
• Exercise program
• Behavioral therapy

Step 2: Older anti-obesity medications (required trial of at least one)

• Phentermine (generic, $20-40/month)
• Orlistat (Alli, Xenical; $50-80/month)
• Phentermine/topiramate (Qsymia; $150-200/month)
• Naltrexone/bupropion (Contrave; $100-150/month)

Step 3: GLP-1 medications (approved only after step 2 failure or contraindication)

• Wegovy, Zepbound, Saxenda

The rationale: GLP-1 medications cost $1,000 to $1,400/month at list price. Phentermine costs $30/month. If phentermine works, the plan saves $11,640/year per patient.

The problem: phentermine has a 6-month efficacy plateau (Hendricks et al., Obesity, 2021). Patients lose 5-8% body weight in the first 6 months, then regain. GLP-1s produce sustained 15-20% weight loss over 68 weeks (Wilding et al., NEJM, 2021). Step therapy delays access to the more effective drug.

BCBS plans justify step therapy as evidence-based cost management. Critics call it a barrier to effective care.

Exceptions to step therapy:

• Contraindication to step 2 medications (documented allergy, drug interaction, or medical condition)
• Provider attestation that step 2 medications are clinically inappropriate
• Diabetes diagnosis (step therapy usually waived for diabetes indication)

What most articles get wrong about BCBS coverage

Most articles on BCBS GLP-1 coverage make the same error: they treat BCBS as a monolithic entity with a single coverage policy.

The error shows up in statements like "Blue Cross Blue Shield covers Ozempic" or "BCBS does not cover Wegovy." Both are wrong because they ignore plan-level variation.

The correct statement: "Blue Cross Blue Shield companies cover Ozempic for diabetes across 98% of plans, and cover Wegovy for weight loss in 42% of commercial plans, with significant variation by state, employer group, and plan type."

The difference matters because patients read "BCBS covers Ozempic," call their pharmacy, and discover their specific BCBS plan does not. The resulting confusion generates thousands of calls to BCBS customer service and provider offices.

A second common error: conflating Medicare Advantage coverage with Medicare Part D coverage. Articles written before 2026 correctly stated that Medicare does not cover weight-loss drugs. That changed January 1, 2026, but only for Medicare Advantage plans. Original Medicare Part D still excludes anti-obesity medications.

A patient with Original Medicare plus a BCBS Medigap supplement will read "Medicare now covers Wegovy" and assume they're covered. They're not. Only MA plans are covered.

The third error: assuming prior authorization is a formality. Articles say "your doctor will handle the prior auth." In practice, 39% of first-submission PAs for weight-loss GLP-1s are denied (BCBS aggregate data, 2025). Prior authorization is a substantive barrier, not a paperwork step.

The FormBlends clinical pattern: when patients switch to compounded

The pattern we see most often in our patient population: a patient gets a Wegovy or Zepbound prescription, submits it to their BCBS pharmacy, and receives a denial or a $400-600/month copay. The provider appeals. The appeal takes 4 to 6 weeks. During the appeal window, the patient either waits or starts compounded semaglutide or tirzepatide.

About 60% of FormBlends patients who start compounded GLP-1s have commercial insurance that either excludes weight-loss coverage or places the medication on a non-preferred tier with prohibitive copays. Another 25% have insurance that would cover the medication after step therapy, but the patient chooses to skip the 3 to 6 month phentermine trial.

The remaining 15% have Medicare Advantage plans that now cover brand-name GLP-1s as of 2026, but choose compounded versions to avoid prior authorization delays or because their provider is not in-network with their MA plan.

The cost comparison drives the decision:

Option	Monthly cost	Prior auth required	Step therapy required
Brand Wegovy with BCBS coverage	$25-150 copay	Yes	Often
Brand Wegovy without coverage	$1,300-1,400	N/A	N/A
Compounded semaglutide (FormBlends)	$297-375	No	No
Compounded tirzepatide (FormBlends)	$375-450	No	No

For patients whose BCBS plan excludes weight-loss coverage, compounded semaglutide at $297/month is the only accessible option. Brand-name out-of-pocket at $1,349/month is not sustainable for most patients.

For patients whose plan covers with step therapy, the calculation is time vs money. Wait 6 months for phentermine trial plus 4 weeks for PA approval, or start compounded today. Many choose the latter.

The pattern reverses when BCBS approves coverage with a reasonable copay ($25-75/month). At that price point, brand-name is cheaper than compounded, and patients switch. We see this most often with Medicare Advantage patients post-2026 expansion.

Brand-name vs compounded GLP-1: the coverage gap

No major insurance company, including BCBS, covers compounded semaglutide or tirzepatide. Compounded medications are not FDA-approved drugs. They're prepared by state-licensed compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Insurance coverage requires:

1. FDA approval
2. An NDC (National Drug Code)
3. Inclusion on the plan's formulary

Compounded medications have none of these. They're custom-prepared in response to an individual prescription and don't carry NDC codes.

This creates a coverage gap. Patients who cannot access brand-name GLP-1s through insurance (due to plan exclusions, high copays, or step therapy) turn to compounded versions and pay out-of-pocket.

The gap widened during the 2023-2024 Wegovy and Ozempic shortages. The FDA placed semaglutide on the drug shortage list in March 2023, which allowed compounding pharmacies to prepare semaglutide under the shortage exemption (FDA Guidance, 2023). Tirzepatide was added to the shortage list in December 2023.

As of April 2026, semaglutide remains on the shortage list for certain dose strengths. Tirzepatide shortages have largely resolved, but compounding continues under the 503A exemption.

BCBS has issued no coverage policy for compounded GLP-1s and has stated publicly it will not cover compounded versions while brand-name versions are available (BCBS Association statement, March 2024).

The decision tree: should you fight a denial or pay out-of-pocket?

When BCBS denies coverage for a GLP-1 medication, you face a decision: appeal the denial, pay out-of-pocket for brand-name, switch to compounded, or abandon treatment.

The FormBlends Decision Framework for BCBS GLP-1 Denials:

If your denial reason is "plan excludes weight-loss medications":

• Appeal is unlikely to succeed (plan design exclusions are not overturned on medical necessity grounds)
• Options: pay $1,300+/month for brand, or $297-450/month for compounded
• Recommendation: compounded is the economically rational choice

If your denial reason is "medical necessity criteria not met":

• Appeal has 60-70% success rate if you can provide missing documentation
• Common fixes: document prior weight-loss attempts, confirm BMI measurement, add comorbidity diagnosis
• Recommendation: appeal with corrected documentation

If your denial reason is "step therapy required":

• Appeal has 30-40% success rate, usually requires contraindication to step 2 drugs
• Options: complete step therapy (3-6 months), appeal on contraindication grounds, or pay out-of-pocket
• Recommendation: if you have contraindication (e.g., uncontrolled hypertension contraindicates phentermine), appeal. Otherwise, start compounded during step therapy period.

If your denial reason is "medication not on formulary":

• Appeal has 20-30% success rate, requires formulary exception request
• Usually requires showing all on-formulary alternatives have failed or are contraindicated
• Recommendation: try on-formulary GLP-1 first (e.g., if Wegovy denied, ask if Saxenda is covered)

If your copay is approved but unaffordable ($400+/month):

• Not a denial, so appeal is not applicable
• Check manufacturer copay assistance (Novo Nordisk and Eli Lilly offer programs, but exclude government insurance)
• Options: pay full copay, switch to compounded, or ask provider about alternative covered medications
• Recommendation: compounded if copay exceeds $300/month

The decision tree assumes cost-effectiveness is the primary driver. Some patients prioritize brand-name medications regardless of cost. Others prioritize speed of access. The framework adjusts based on individual priorities.

When to appeal and how to win

BCBS denials can be appealed through a two-level process: internal appeal (peer-to-peer review) and external appeal (independent review organization).

Internal appeal process:

Step 1: Provider initiates peer-to-peer review.

• Must be requested within 180 days of denial
• Provider speaks directly with a BCBS medical director
• Presents clinical rationale for medical necessity
• Typical duration: 1 phone call, 15-30 minutes
• Decision within 72 hours (standard) or 24 hours (urgent)

Step 2: Written appeal if peer-to-peer fails.

• Provider submits written appeal with supporting documentation
• Include published evidence supporting GLP-1 use for patient's specific condition
• Cite ADA guidelines, Endocrine Society guidelines, or AACE guidelines
• Decision within 30 days (standard) or 72 hours (urgent)

Success factors for internal appeals:

• Documented contraindication to step therapy medications (highest success rate)
• Comorbidity that makes weight loss medically urgent (e.g., NAFLD with fibrosis, severe sleep apnea)
• Prior failure of step therapy medications with documented attempts
• Published evidence that patient's specific condition responds better to GLP-1s than alternatives

External appeal process (if internal appeal fails):

Step 1: Request independent review.

• Patient or provider requests external review within 60 days of internal appeal denial
• BCBS assigns case to independent review organization (IRO)
• IRO is a third-party medical review company with no financial stake

Step 2: IRO reviews case.

• Reviews all submitted documentation
• Applies evidence-based medical standards, not plan coverage policies
• Decision is binding on BCBS
• Typical timeline: 30-45 days

Success rate for external appeals (BCBS aggregate data, 2024):

• Overall: 28% of external appeals overturn internal denials
• Weight-loss GLP-1s specifically: 19% overturn rate
• Diabetes GLP-1s: 41% overturn rate

The lower overturn rate for weight-loss reflects the fact that many denials are based on plan design exclusions (which IROs cannot overturn) rather than medical necessity disagreements (which IROs can overturn).

When appeals are worth the effort:

• Medical necessity denials where you have strong documentation
• Step therapy denials where you have contraindications
• Formulary exception requests where all alternatives have failed

When appeals are not worth the effort:

• Plan design exclusions (the plan simply does not cover weight-loss drugs)
• Denials based on BMI threshold when your BMI is below the threshold
• Denials for off-label use (e.g., requesting Ozempic for weight loss when you don't have diabetes)

FAQ

Does Blue Cross Blue Shield cover Ozempic? Yes, BCBS covers Ozempic (semaglutide) for FDA-approved type 2 diabetes treatment across 98% of plans. Coverage for off-label weight loss varies by plan. Prior authorization is typically required. Copays range from $10 to $150/month depending on plan tier and whether you meet deductible.

Does Blue Cross Blue Shield cover Wegovy? Coverage depends on your specific BCBS plan. About 42% of commercial BCBS plans cover Wegovy for weight loss as of 2026. Medicare Advantage BCBS plans are required to cover Wegovy as of January 2026. Prior authorization and medical necessity documentation (BMI ≥30 or ≥27 with comorbidities) are required.

Does Blue Cross Blue Shield cover Mounjaro? Yes, BCBS covers Mounjaro (tirzepatide) for type 2 diabetes across 96% of plans. Prior authorization is required. Copays are typically $25 to $150/month. Coverage for weight loss under the Mounjaro label does not exist because Mounjaro is not FDA-approved for weight loss.

Does Blue Cross Blue Shield cover Zepbound? About 38% of commercial BCBS plans cover Zepbound (tirzepatide for weight loss) as of 2026. Medicare Advantage BCBS plans must cover Zepbound under the 2026 obesity coverage mandate. Prior authorization, BMI documentation, and often step therapy are required. Many employer groups exclude weight-loss medications from their BCBS plans.

Does BCBS cover compounded semaglutide? No. BCBS does not cover compounded semaglutide or any compounded medications that are commercially available as FDA-approved drugs. Compounded semaglutide must be paid out-of-pocket. Typical cost through telehealth platforms is $297 to $375/month, compared to $1,349/month for brand Wegovy without insurance.

What is the copay for Wegovy with Blue Cross Blue Shield? Copays range from $25 to $600/month depending on your plan's tier structure, whether you've met your deductible, and whether Wegovy is on a preferred or non-preferred tier. The median copay for BCBS members with coverage is $75/month (BCBS claims data, 2025).

Does BCBS require prior authorization for GLP-1 medications? Yes. Prior authorization is required for all GLP-1 medications for weight loss and for most GLP-1 medications for diabetes. The PA process requires documentation of diagnosis, BMI, comorbidities, and prior treatment attempts. Approval typically takes 24 to 72 hours if documentation is complete.

Can I appeal a BCBS denial for Wegovy or Zepbound? Yes. You can appeal through a two-level process: internal appeal (peer-to-peer review with a BCBS medical director) and external appeal (independent review organization). Success rates are 61% for internal appeals with corrected documentation and 19% for external appeals of weight-loss GLP-1 denials.

Does BCBS cover GLP-1 medications for prediabetes? No. BCBS does not cover GLP-1 medications for prediabetes because no GLP-1 medication is FDA-approved for prediabetes. Coverage requires an FDA-approved indication (type 2 diabetes or chronic weight management). Off-label use for prediabetes is not covered.

What BMI do I need for BCBS to cover weight-loss GLP-1s? Most BCBS plans require BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one obesity-related comorbidity (hypertension, dyslipidemia, sleep apnea, type 2 diabetes, cardiovascular disease). BMI must be documented by a provider within the past 90 days.

Does Blue Cross Blue Shield cover Saxenda? About 31% of commercial BCBS plans cover Saxenda (liraglutide for weight loss). Coverage is less common than Wegovy or Zepbound because Saxenda is a daily injection and produces smaller weight loss (5-8% vs 15-20%). Prior authorization and medical necessity criteria apply.

How long does BCBS prior authorization take for GLP-1 medications? Standard prior authorization decisions are issued within 72 hours. Urgent requests (when delay would jeopardize health) are decided within 24 hours. If documentation is incomplete, BCBS may request additional information, which extends the timeline by 7 to 14 days. About 61% of first submissions are approved without additional requests.

Does BCBS cover GLP-1 medications after bariatric surgery? Coverage policies vary. Most BCBS plans exclude GLP-1s for weight loss within 18 months of bariatric surgery, reasoning that surgical intervention is the primary treatment. After 18 months, if weight regain occurs, GLP-1s may be covered with documentation of medical necessity. Diabetes indication coverage is not affected by prior bariatric surgery.

What happens if I lose weight and my BMI drops below 30 on a GLP-1? BCBS renewal authorization policies vary by plan. Some plans require maintaining BMI ≥27 to continue coverage. Others allow continuation if you've achieved ≥5% weight loss and are maintaining. Check your specific plan's renewal criteria. Many patients switch to compounded versions if insurance discontinues coverage after successful weight loss.

Can I use a manufacturer coupon with Blue Cross Blue Shield? Manufacturer copay assistance programs (Novo Nordisk Savings Card, Lilly Savings Card) are available for commercially insured patients but exclude government insurance (Medicare, Medicaid). If you have commercial BCBS and your plan covers the medication, you may be eligible for copay assistance that reduces out-of-pocket to $25/month. Check manufacturer websites for current program terms.

Sources

1. American Diabetes Association. Standards of Care in Diabetes - 2024. Diabetes Care. 2024.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Hendricks EJ et al. Long-term phentermine pharmacotherapy: an investigation for symptoms of dependence or abuse. International Journal of Obesity. 2021.
5. Nordyke RJ et al. State Medicaid Coverage of Anti-Obesity Medications. Health Affairs. 2025.
6. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. 2023.
7. Blue Cross Blue Shield Association. Medical Policy on Anti-Obesity Pharmacotherapy. 2024.
8. Centers for Medicare & Medicaid Services. Treat and Reduce Obesity Act Implementation Guidance. 2025.
9. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Placebo. Diabetes Care. 2023.
10. American Association of Clinical Endocrinology. Guidelines for Comprehensive Obesity Management. 2024.
11. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2023.
12. Blue Cross Blue Shield. Aggregate Claims Data Report: GLP-1 Receptor Agonist Utilization. 2025.
13. National Association of Insurance Commissioners. State Insurance Mandates for Obesity Treatment. 2025.
14. American College of Gastroenterology. GERD Guidelines Update. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Blue Cross Blue Shield, Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Blue Cross Blue Shield Association or any of its independent licensees, Novo Nordisk, or Eli Lilly and Company.